AMICUS THERAPEUTICS, INC. (FOLD) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
FOLD currently has 308M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 1.64% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 04, 2025 |
10-Q filing | 308.5M shares outstanding |
310M | 0 |
| May 01, 2025 |
10-Q filing | 307.7M shares outstanding |
310M | 0 |
| Feb 19, 2025 |
10-K filing | 304.4M shares outstanding |
300M | 0 |
| Nov 06, 2024 |
10-Q filing | 304.7M shares outstanding |
300M | 0 |
| Aug 08, 2024 |
10-Q filing | 303.8M shares outstanding |
300M | 0 |
| May 09, 2024 |
10-Q filing | 302.9M shares outstanding |
300M | 0 |
| Feb 28, 2024 |
10-K filing | 295.2M shares outstanding |
300M | 0 |
| Nov 08, 2023 |
10-Q filing | 295.8M shares outstanding |
300M | 0 |
| Oct 02, 2023 |
8-K filing: Amicus Therapeutics entered into a loan agreement for a $400 million senior secured term loan and a securities purchase agreement for a private placement of 2,467,104 shares of common stock at $12.16 per share, with gross proceeds expected to be $30,000,000. ($30.0M proceeds) |
290M | 0 |
| Aug 08, 2023 |
10-Q filing | 292.8M shares outstanding |
290M | 0 |
| May 10, 2023 |
10-Q filing | 291.3M shares outstanding |
290M | 0 |
| Mar 01, 2023 |
10-K filing | 289.1M shares outstanding |
290M | 0 |
| Nov 07, 2022 |
10-Q filing | 289.2M shares outstanding |
290M | 0 |
| Aug 04, 2022 |
10-Q filing | 292.0M shares outstanding |
290M | 0 |
| May 10, 2022 |
10-Q filing | 288.5M shares outstanding |
290M | 0 |
| Feb 24, 2022 |
10-K filing | 271.4M shares outstanding |
270M | 0 |
| Nov 09, 2021 |
10-Q filing | 267.5M shares outstanding |
270M | 0 |
| Aug 05, 2021 |
10-Q filing | 266.4M shares outstanding |
270M | 0 |
| May 10, 2021 |
10-Q filing | 266.1M shares outstanding |
270M | 0 |
| Mar 01, 2021 |
10-K filing | 264.3M shares outstanding |
260M | 0 |
| Jan 29, 2021 |
S-3 filing: This S-3 filing relates to the resale of up to 2,554,999 shares of common stock of Amicus Therapeutics, Inc. by selling stockholders, underlying warrants acquired in connection with a Note and Warrant Purchase Agreement. |
260M | 2.6M |
| Nov 05, 2020 |
10-Q filing | 260.6M shares outstanding |
260M | 0 |
| Aug 10, 2020 |
10-Q filing | 258.8M shares outstanding |
260M | 0 |
| May 07, 2020 |
10-Q filing | 257.4M shares outstanding |
260M | 0 |
| Mar 02, 2020 |
10-K filing | 189.4M shares outstanding |
190M | 0 |